In conclusion, these observations indicate that PHB1 and PHB2 activity contribute to tumor cell survival in the context of mitochondrial protection and therefore strengthen the potential value of these proteins as therapeutic targets in the treatment hematologic cancers. This evidence concerns the gene PHB2 and hematopoietic and lymphoid cell neoplasm.